Skip to content

New Amendment to 1945 Drug Rules Bars Fraudulent Submissions

By News Analysis India · · 1 min read

NEW DELHI, Aug 6 — In a decisive step toward greater transparency, the central health ministry announced a modification to the Drug Rules of 1945, formally recorded in Gazette Notification No. 756 (E) dated October 16, 2025. The amendment adds a specific clause that authorises the licensing authority—whether state or central—to deny any forthcoming application from a firm that has presented counterfeit or fabricated evidence in any earlier filing.

Previously, the punitive response was limited to rejection of the current application or revocation of an existing licence. The revised rule now includes a time‑bound ban on submitting new licences, following a notice of cause and a prescribed appeal mechanism. This escalated sanction is intended to curb manipulation of data that underpin regulatory evaluations of drug quality, safety, and therapeutic benefit.

The ministry emphasised that reliable, peer‑reviewed data remain the backbone of pharmaceutical approval processes. The amendment underscores India’s commitment to fortify its regulatory architecture, stimulate ethical practices among industry players, and safeguard public health from the dangers of substandard medicines.